Thermo Fisher Scientific (TMO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of eleven director nominees for the board for the upcoming term.
An advisory vote will be held to approve named executive officer compensation.
Ratification of PricewaterhouseCoopers LLP as independent auditors for 2026 is on the agenda.
Additional business may be addressed if properly brought before the meeting.
Board of directors and corporate governance
Eleven individuals have been nominated for election to the board, including Marc N. Casper and Karen S. Lynch.
Executive compensation and say-on-pay
Shareholders are asked to provide an advisory vote on the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Thermo Fisher Scientific
- Executive compensation program revised for 2026 to enhance pay-for-performance and shareholder alignment.TMO
Proxy filing11 May 2026 - Q1 2026 delivered 6% revenue growth, 11% GAAP EPS growth, and robust segment results.TMO
Q1 20261 May 2026 - 2025 saw strong growth, major compensation changes, and continued focus on governance and ESG.TMO
Proxy filing7 Apr 2026 - Entering 2026 with strong growth, innovation, and strategic expansion across key markets.TMO
47th Annual Raymond James Institutional Investor Conference26 Mar 2026 - Targets 7%-9% organic growth, driven by innovation, M&A, and operational excellence.TMO
Investor Day 20243 Feb 2026 - Q4 revenue up 7%, EPS and free cash flow strong, with major acquisitions and innovation.TMO
Q4 20253 Feb 2026 - Q2 revenue dipped 1% but EPS grew, and guidance was raised after the Olink acquisition.TMO
Q2 20243 Feb 2026 - Gradual market recovery, innovation, and strategic M&A drive a positive long-term outlook.TMO
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 2024 revenue was $10.6B with raised adjusted EPS guidance and flat organic growth.TMO
Q3 202419 Jan 2026